Entero Therapeutics Inc.

The momentum for this stock is not very good. Entero Therapeutics Inc. is not very popular among insiders. Tradey thinks it is not wise to invest in Entero Therapeutics Inc..

News

Entero Therapeutics signs letter of intent with Data Vault Holdings

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Entero Therapeutics Signs Letter of Intent to License and Commercialize Remote Patient and Machine Vision Clinical Trial Management Platform from Data Vault Holdings

Globe Newswire Entero Therapeutics to integrate applications in planned Phase 3 study of latiglutenase for celiac disease and explore additional uses of technology in clinical trial complianceBOCA RATON, Fla...\n more…

Entero Therapeutics receives Nasdaq notification regarding delayed form 10-Q

Seeking Alpha - Healthcare Entero Therapeutics receives Nasdaq notification regarding delayed form 10-Q...\n more…

Entero Therapeutics receives noncompliance notification from Nasdaq

Entero Therapeutics, Inc. Receives Nasdaq Notification Regarding Delayed Form 10-Q

Globe Newswire BOCA RATON, Fla., Aug. 23, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), ( Entero Therapeutics or the Company ), a clinical-stage biopharmaceutical company specializing in...\n more…

Entero Therapeutics' Chairman and CEO James Sapirstein Provides Business Update with Focus on Latiglutenase Development Program

Globe Newswire BOCA RATON, Fla., July 31, 2024 (GLOBE NEWSWIRE) -- Entero Therapeutics, Inc., (NASDAQ: ENTO), ( Entero Therapeutics or the Company ), a clinical-stage biopharmaceutical company specializing in...\n more…